Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11β-hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone

Journal of Steroid Biochemistry and Molecular Biology

Volumn 166, Issue , 2017, Pages 54-67

  du Toit, Therina ^a   Bloem, Liezl M ^a   Quanson, Jonathan L ^a   Ehlers, Riaan ^a   Serafin, Antonio M ^b   Swart, Amanda C ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

11K DHT; 11keto testosterone (11KT); Adrenal 11 hydroxy androstenedione (11 OHA4); Castration resistant prostate cancer (CRPC); LC MS MS; LNCaP prostate cancer cell model; PNT2 epithelial prostate cell model

Indexed keywords

11 BETAHYDROXYTESTOSTERONE; 11 KETODIHYDROTESTOSTERONE; 11 OXOTESTOSTERONE; 11BETA HYDROXYANDROSTENEDIONE; 11BETA HYDROXYTESTOSTERONE; ANDROSTANEDIOL; ANDROSTANEDIONE; ANDROSTANOLONE; ANDROSTERONE; TESTOSTERONE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG; 11-HYDROXYANDROSTENEDIONE; 11-KETODIHYDROTESTOSTERONE; 11-KETOTESTOSTERONE; ANDROGEN; ANDROSTENEDIONE; GLUCURONIC ACID; STEROID;

AGED; ANDROGEN METABOLISM; CANCER TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LNCAP CELL LINE; MALE; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; REVIEW; STEROID ANALYSIS; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE CONVERGENCE CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADRENAL GLAND; ANALOGS AND DERIVATIVES; CHEMISTRY; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ADRENAL GLANDS; AGED; ANDROGENS; ANDROSTENEDIONE; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIC ACID; HUMANS; HYDROXYTESTOSTERONES; MALE; PROSTATIC NEOPLASMS; STEROIDS; TANDEM MASS SPECTROMETRY; TESTOSTERONE;

EID: 85003601717     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.06.009     Document Type: Review

References (72)

1. [1] Stanbrough, M., Bubley, G.J., Ross, K., Golub, T.R., Rubin, M.A., Penning, T.M., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66 (2006), 2815–2825, 10.1158/0008-5472.CAN-05-4000.
2. [2] Luu-The, V., Bélanger, A., Labrie, F., Androgen biosynthetic pathways in the human prostate. Best Pract. Res. Clin. Endocrinol. Metab. 22 (2008), 207–221, 10.1016/j.beem.2008.01.008.
3. [3] Montgomery, R.B., Mostaghel, E.A., Vessella, R., Hess, D.L., Kalhorn, T.F., Higano, C.S., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68 (2008), 4447–4454, 10.1158/0008-5472.CAN-08-0249.
4. [4] Stein, M.N., Goodin, S., Dipaola, R.S., Abiraterone in prostate cancer: a new angle to an old problem. Clin. Cancer Res. 18 (2012), 1848–1854, 10.1158/1078-0432.CCR-11-1805.
5. [5] Labrie, F., Intracrinology: its impact on prostate cancer. Curr. Opin. Urol. 3 (1993), 381–387.
6. [6] Larsen, J.F., Walter, S., Krarup, T., Complete androgen blockade as primary treatment for advanced metastatic cancer of the prostate. Int. Urol. Nephrol. 22 (1990), 249–255, 10.1007/BF02550402.
7. [7] Sharifi, N., Auchus, R.J., Steroid biosynthesis and prostate cancer. Steroids 77 (2012), 719–726, 10.1016/j.steroids.2012.03.015.
8. [8] Rege, J., Nakamura, Y., Satoh, F., Morimoto, R., Kennedy, M.R., Layman, L.C., et al. Liquid chromatography – tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J. Clin. Endocrinol. Metab. 98 (2013), 1182–1188, 10.1210/jc.2012-2912.
9. [9] Bloem, L.M., Storbeck, K.H., Swart, P., Du Toit, T., Schloms, L., Swart, A.C., Advances in the analytical methodologies: profiling steroids in familiar pathways-challenging dogmas. J. Steroid Biochem. Mol. Biol. 153 (2015), 80–92, 10.1016/j.jsbmb.2015.04.009.
10. [10] Swart, A.C., Storbeck, K., 11β-Hydroxyandrostenedione: downstream metabolism by 11βHSD 17βHSD and SRD5A produces novel substrates in familiar pathways. Mol. Cell. Endocrinol. 408 (2015), 114–123, 10.1016/j.mce.2014.12.009.
11. 19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?. Mol. Cell. Endocrinol. 377 (2013), 135–146, 10.1016/j.mce.2013.07.006.
12. [12] Bloem, L.M., Storbeck, K.H., Schloms, L., Swart, A.C., 11β-Hydroxyandrostenedione returns to the steroid arena: biosynthesis, metabolism and function. Molecules 18 (2013), 13228–13244, 10.3390/molecules181113228.
13. [13] Miller, W.L., Auchus, R.J., The molecular biology, biochemistry, and phsiology of human steroidogenesis and its disorders. Endocr. Rev. 32 (2011), 81–151, 10.1210/er.2010-0013.
14. [14] Rege, J., Rainey, W.E., The steroid metabolome of adrenarche. J. Endocrinol. 214 (2012), 133–143, 10.1530/JOE-12-0183.
15. [15] Mostaghel, E.A., Steroid hormone synthetic pathways in prostate cancer. Transl. Androl. Urol. 2 (2013), 212–227, 10.3978/j.issn.2223-4683.2013.09.16.
16. [16] Mindnich, R., Möller, G., Adamski, J., The role of 17 beta-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 218 (2004), 7–20, 10.1016/j.mce.2003.12.006.
17. [17] Chang, K., Li, R., Papari-zareei, M., Watumull, L., Daniel, Y., Auchus, R.J., Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl. Acad. Sci. 108 (2011), 13728–13733, 10.1073/pnas.1107898108/-/DCSupplemental www.pnas.org/cgi/doi/10.1073/pnas.1107898108.
18. [18] Swart, A.C., Schloms, L., Storbeck, K., Bloem, L.M., Du Toit, T., Quanson, J.L., et al. 11β-Hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione. J. Steroid Biochem. Mol. Biol. 138 (2013), 132–142, 10.1016/j.jsbmb.2013.04.010.
19. [19] Chouinard, S., Barbier, O., Bélanger, A., UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J. Biol. Chem. 282 (2007), 33466–33474, 10.1074/jbc.M703370200.
20. [20] Barbier, O., Bélanger, A., Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate., Best Pract. Res. Clin. Endocrinol. Metab. 22 (2008), 259–270, 10.1016/j.beem.2008.01.001.
21. [21] Beaulieu, M., Levesque, E., Hum, D.W., Belanger, A., Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J. Biol. Chem. 271 (1996), 22855–22862, 10.1074/jbc.271.37.22855.
22. [22] Tukey, R.H., Strassburg, C.P., Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40 (2000), 581–616, 10.1146/annurev.pharmtox.40.1.581.
23. [23] Mostaghel, E.A., Zhang, A., Plymate, S., UDP-glucuronosyltransferase enzymes in prostate cancer progression: is only androgen catabolism involved?. Eur. Urol., 2015, 9–11, 10.1016/j.eururo.2015.08.025.
24. [24] Wu, L., Einstein, M., Geissler, W.M., Chan, H.K., Elliston, K.O., Andersson, S., Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J. Biol. Chem. 268 (1993), 12964–12969.
25. [25] Titus, M.A., Gregory, C.W., Ford, O.H., Schell, M.J., Maygarden, S.J., Mohler, J.L., Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin. Cancer Res. 11 (2005), 4365–4371, 10.1158/1078-0432.CCR-04-0738.
26. [26] Muthusamy, S., Andersson, S., Kim, H., Butler, R., Waage, L., Bergerheim, U., et al. Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc. Natl. Acad. Sci. 108 (2011), 20090–20094, 10.1073/pnas.1117772108.
27. [27] Huang, X.F., Luu-The, V., Molecular characterization of a first human 3(α → β)-hydroxysteroid epimerase. J. Biol. Chem. 275 (2000), 29452–29457, 10.1074/jbc.M000562200.
28. [28] Belyaeva, O.V., Chetyrkin, S.V., Clark, A.L., Kostereva, N.V., SantaCruz, K.S., Chronwall, B.M., et al. Role of microsomal retinol/sterol dehydrogenase-like short-chain dehydrogenases/reductases in the oxidation and epimerization of 3α-hydroxysteroids in human tissues. Endocrinology 148 (2007), 2148–2156, 10.1210/en.2006-1491.
29. [29] Bauman, D.R., Steckelbroeck, S., Williams, M.V., Peehl, D.M., Penning, T.M., Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α, 17β-diol to 5α-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol. Endocrinol. 20 (2006), 444–458, 10.1210/me.2005-0287.
30. [30] Dorfman, R.I., In vivo metabolism of neutral steroid hormones. J. Clin. Endocrinol. Metab. 14 (1954), 318–325, 10.1210/jcem-14-3-318.
31. [31] Turgeon, D., Carrier, J.-S., Levesques, E., Hum, D.W., Belanger, A., Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2 B subfamily members. Endocrinology 142 (2001), 778–787, 10.1210/endo.142.2.7958.
32. [32] Gazdar, A.F., Oie, H.K., Shackleton, C.H., Chen, T.R., Triche, T.J., Myers, C.E., et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50 (1990), 5488–5496.
33. [33] Sten, T., Bichlmaier, I., Kuuranne, T., Leinonen, A., Yli-kauhaluoma, J., Finel, M., UDP-Glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab. Dispos. 37 (2009), 417–423, 10.1124/dmd.108.024844.concentration.
34. [34] Schloms, L., Storbeck, K.-H., Swart, P., Gelderblom, W.C.A., Swart, A.C., The influence of Aspalathus linearis (Rooibos) and dihydrochalcones on adrenal steroidogenesis: quantification of steroid intermediates and end products in H295R cells. J. Steroid Biochem. Mol. Biol. 128 (2012), 128–138, 10.1016/j.jsbmb.2011.11.003.
35. [35] J.L. Quanson, M. Stander, E. Pretorius, A. Taylor, C. Jenkinson, K.-H. Storbeck, High-throughput analysis of 19 endogenous androgenic steroids by ultra-performance convergence chromatography tandem mass spectrometry (Personal communication).
36. [36] Taylor, P.J., Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clin. Biochem. 38 (2005), 328–334, 10.1016/j.clinbiochem.2004.11.007.
37. 19 substrates, MSc thesis (2015) Stellenbosch University, http://scholar.sun.ac.za/handle/10019.1/97057.
38. [38] Berthaut, I., Portois, M., Cussenot, O., Mowszowicz, I., Human prostatic cells in culture: different testosterone metabolic profile in epithelial cells and fibroblasts from normal or hyperplastic prostates. J. Steroid Biochem. Molec. Biol. 58 (1996), 235–242.
39. [39] Chouinard, S., Pelletier, G., Bélanger, A., Barbier, O., Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 147 (2006), 5431–5442, 10.1210/en.2006-0229.
40. [40] Berthon, P., Cussenot, O., Hopwood, L., Leduc, A., Maitland, N., Functional expression of SV40 in normal human prostatic epithelial and fibroblastic cells − differentiation pattern of nontumorigenic cell-lines. Int. J. Oncol. 6 (1995), 333–343.
41. [41] Guillemette, C., Belanger, A., Glucuronosyltransferase activity in human cancer cell line LNCaP. Mol. Cell. Endocrinol. 107 (1995), 131–139, 10.1016/0303-7207(94)03434-U.
42. [42] Bélanger, G., Beaulieu, M., Marcotte, B., Levesque, E., Guillemette, C., Hum, D.W., et al. Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Mol. Cell. Endocrinol. 113 (1995), 165–173, 10.1016/0303-7207(95)03627-J.
43. [43] Bélanger, A., Hum, D.W., Beaulieu, M., Levesque, E., Guillemette, C., Tchernof, A., et al. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J. Steroid Biochem. Mol. Biol. 65 (1998), 301–310, 10.1016/S0960-0760(97)00183-0.
44. [44] Dovio, A., Sartori, M.L., De Francia, S., Mussino, S., Perotti, P., Saba, L., et al. Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines. J. Steroid Biochem. Mol. Biol. 116 (2009), 29–36, 10.1016/j.jsbmb.2009.04.007.
45. [45] Page, N., Warriar, N., Govindan, M.V., 11β-Hydroxysteroid dehydrogenase and tissue specificity of androgen action in human prostate cancer cell LNCaP. J. Steroid Biochem. Mol. Biol. 49 (1994), 173–181, 10.1016/0960-0760(94)90008-6.
46. [46] Beaulieu, M., Levesque, E., Hum, D.W., Belanger, A., Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol. Chem. 271 (1996), 22855–22862.
47. [47] Penning, T.M., Bauman, D.R., Jin, Y., Rizner, T.L., Identification of the molecular switch that regulates access of 5α-DHT to the androgen receptor. Mol. Cell. Endocrinol. 265–266 (2007), 77–82, 10.1016/j.mce.2006.12.007.
48. [48] Mitsiades, N., Sung, C.C., Schultz, N., Danila, D.C., He, B., Eedunuri, V.K., et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 72 (2012), 6142–6152, 10.1158/0008-5472.CAN-12-1335.
49. [49] Biancolella, M., Valentini, A., Minella, D., Vecchione, L., Amico, F.D., Chillemi, G., et al. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest. New Drugs. 25 (2007), 491–497, 10.1007/s10637-007-9070-7.
50. [50] Fujimura, T., Takahashi, S., Urano, T., Kumagai, J., Murata, T., Takayama, K., et al. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 74 (2009), 391–397, 10.1016/j.urology.2009.02.033.
51. [51] Usmani, K.A., Rose, R.L., Hodgson, E., Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals. Drug Metab. Dispos. 31 (2003), 384–391, 10.1124/dmd.31.4.384.
52. [52] Moilanen, A.-M., Hakkola, J., Vaarala, M.H., Kauppila, S., Hirvikoski, P., Vuoristo, J.T., et al. Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis 28 (2007), 916–921, 10.1093/carcin/bgl222.
53. [53] Finnstrom, N., Bjelfman, C., Soderstrom, T.G., Smith, G., Egevad, L., Norlen, B.J., et al. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest. 31 (2001), 880–886, 10.1046/j.1365-2362.2001.00893.x.
54. [54] Agúndez, J.A.G., Martínez, C., Olivera, M., Gallardo, L., Ladero, J.M., Rosado, C., et al. Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br. J. Cancer. 78 (1998), 1361–1367, 10.1038/bjc.1998.685.
55. [55] Yamakoshi, Y., Kishimoto, T., Sugimura, K., Kawashima, H., Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem. Biophys. Res. Commun. 260 (1999), 676–681, 10.1006/bbrc.1999.0960.
56. [56] Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA., Drug Metab. Dispos 30 (2002), 1108–1114, 10.1124/dmd.30.10.1108.
57. [57] Attar, R.M., Takimoto, C.H., Gottardis, M.M., Castration-resistant prostate cancer: locking up the molecular escape routes. Clin. Cancer Res. 15 (2009), 3251–3255, 10.1158/1078-0432.CCR-08-1171.
58. [58] Sharifi, N., The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. J. Investig. Med. 60 (2012), 1–8 doi:10.231/JIM.0b013e31823874a4.
59. [59] van der Sluis, T.M., Vis, A.N., van Moorselaar, R.J.A., Bui, H.N., Blankenstein, M.A., Meuleman, E.J.H., et al. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer. BJU Int. 109 (2012), 176–182, 10.1111/j.1464-410X.2011.10651.x.
60. [60] Heracek, J., Hampl, R., Richard, H., Hill, M., Martin, H., Starka, L., et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72 (2007), 375–380, 10.1016/j.steroids.2007.01.004.
61. [61] Monostory, K., Dvorak, Z., Steroid regulation of drug-metabolizing cytochromes P450. Curr. Drug Metab. 12 (2011), 154–172, 10.2174/138920011795016854.
62. [62] Choi, M.H., Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R., Characterization of testosterone 11β-hydroxylation catalyzed by human liver microsomal cytochromes P450. Pharmacology 33 (2005), 714–718, 10.1124/dmd.104.003327.
63. [63] Zielinski, J., Mevissen, M., Inhibition of in vitro metabolism of testosterone in human, dog and horse liver microsomes to investigate species differences. Toxicol. Vitro 29 (2015), 468–478, 10.1016/j.tiv.2014.12.018.
64. [64] Bélanger, B., Bélanger, A., Labrie, F., Dupont, A., Cusan, L., Monfette, G., Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J. Steroid Biochem. 32 (1989), 695–698.
65. [65] Nishiyama, T., Ikarashi, T., Hashimoto, Y., Wako, K., Takahashi, K., The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J. Urol. 178 (2007), 1282–1289, 10.1016/j.juro.2007.05.138.
66. [66] Oefelein, M.G., Feng, A., Scolieri, M.J., Ricchiutti, D., Resnick, M.I., Reassessment of the definition of castrate levels of testosterone: implications for clinicaldecision making. Urology 56 (1995), 1021–1024, 10.1016/S0090-4295(00)00793-7.
67. [67] Nishiyama, T., Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature. Urol. Oncol. 32 (2014), 38.e17–38.e28, 10.1016/j.urolonc.2013.03.007.
68. [68] Mostaghel, E.A., Beyond T and DHT – novel steroid derivatives capable of wild type androgen receptor activation. Int. J. Biol. Sci. 10 (2014), 602–613, 10.7150/ijbs.8844.
69. [69] Yeap, B.B., Almeida, O.P., Hyde, Z., Norman, P.E., Chubb, S.A.P., Jamrozik, K., In men older than 70 years, total testosterone remains stable while free testosterone declines with age the health in men study. Eur. J. Endocrinol. 156 (2007), 585–594, 10.1530/EJE-06-0714.
70. [70] Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza, P., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368 (2013), 138–148, 10.1056/NEJMoa1209096.
71. [71] de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364 (2011), 1995–2005.
72. [72] Seo, Y.-K., Mirkheshti, N., Song, C.S., Kim, S., Dodds, S., Ahn, S.C., et al. SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer. Mol. Endocrinol. 27 (2013), 925–939, 10.1210/me.2012-1369.